{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-039326","form_type":"8-K","ticker":"IDXX","cik":"0000874716","company_name":"IDEXX LABORATORIES INC /DE","filed_at":"2021-07-30T23:59:59+00:00","discovered_at":"2026-05-14T18:04:21.017510+00:00","generated_at":"2026-06-30T00:37:57.904694+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"IDEXX Q2 revenue $826M (+30% reported, +25% organic); raises FY 2021 guidance","bullets":["EPS of $2.34, up 36% as reported and 33% comparable basis.","CAG Diagnostics recurring revenue grew 30% reported, 26% organic.","2021 revenue guidance raised to $3,170M-$3,205M (17%-18.5% reported growth).","2021 EPS outlook raised to $8.20-$8.36; operating margin forecast 28.6%-29.1%.","U.S. same-store clinical visit growth 13% in Q2; premium instrument placements doubled YoY."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-039326","json":"https://secwatch.observer/filing/0001564590-21-039326.json","markdown":"https://secwatch.observer/filing/0001564590-21-039326.md","text":"https://secwatch.observer/filing/0001564590-21-039326.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874716/000156459021039326/0001564590-21-039326-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874716/000156459021039326/idxx-8k_20210730.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T00:37:57.904694+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}